Anna Protopapas - Net Worth and Insider Trading

Anna Protopapas Net Worth

The estimated net worth of Anna Protopapas is at least $620,873 dollars as of 2024-04-29. Anna Protopapas is the Director of Mersana Therapeutics Inc and owns about 197,416 shares of Mersana Therapeutics Inc (MRSN) stock worth over $620,873. Anna Protopapas is also the Director of Nuvalent Inc and owns about 0 shares of Nuvalent Inc (NUVL) stock worth over $0. Details can be seen in Anna Protopapas's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Anna Protopapas has not made any transactions after 2024-01-16 and currently still holds the listed stock(s).

Transaction Summary of Anna Protopapas

Anna Protopapas Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Anna Protopapas owns 5 companies in total, including Dicerna Pharmaceuticals Inc (DRNA) , Mersana Therapeutics Inc (MRSN) , and Bioverativ Inc (BIVV) among others .

Click here to see the complete history of Anna Protopapas’s form 4 insider trades.

Insider Ownership Summary of Anna Protopapas

Ticker	Comapny	Transaction Date	Type of Owner
DRNA	Dicerna Pharmaceuticals Inc	2020-06-15	director
MRSN	Mersana Therapeutics Inc	2024-01-16	director & President and CEO
BIVV	Bioverativ Inc	2018-03-08	director
ARIA	ARIAD Pharmaceuticals Inc	2017-02-16	director
NUVL	Nuvalent Inc	2023-12-18	director

Anna Protopapas Latest Holdings Summary

Anna Protopapas currently owns a total of 2 stocks. Among these stocks, Anna Protopapas owns 197,416 shares of Mersana Therapeutics Inc (MRSN) as of January 16, 2024, with a value of $620,873 and a weighting of 100%. Anna Protopapas also owns 0 shares of Nuvalent Inc (NUVL) as of December 18, 2023, with a value of $0 and a weighting of 0%.

Latest Holdings of Anna Protopapas

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MRSN	Mersana Therapeutics Inc	2024-01-16	197,416	3.15	620,873
NUVL	Nuvalent Inc	2023-12-18	0	67.24	0

Holding Weightings of Anna Protopapas

Anna Protopapas Form 4 Trading Tracker

According to the SEC Form 4 filings, Anna Protopapas has made a total of 3 transactions in Mersana Therapeutics Inc (MRSN) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Mersana Therapeutics Inc is the sale of 29,399 shares on January 16, 2024, which brought Anna Protopapas around $79,671.

According to the SEC Form 4 filings, Anna Protopapas has made a total of 1 transactions in Nuvalent Inc (NUVL) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Nuvalent Inc is the sale of 5,000 shares on December 18, 2023, which brought Anna Protopapas around $378,350.

Insider Trading History of Anna Protopapas

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Anna Protopapas Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Anna Protopapas Ownership Network

Ownership Network List of Anna Protopapas

No Data

Ownership Network Relation of Anna Protopapas

Anna Protopapas Owned Company Details

What does Dicerna Pharmaceuticals Inc do?

Who are the key executives at Dicerna Pharmaceuticals Inc?

Anna Protopapas is the director of Dicerna Pharmaceuticals Inc. Other key executives at Dicerna Pharmaceuticals Inc include See Remarks Bob D Brown , EVP & Chief Medical Officer Shreeram Aradhye , and director & President and CEO Douglas Fambrough .

Dicerna Pharmaceuticals Inc (DRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dicerna Pharmaceuticals Inc (DRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dicerna Pharmaceuticals Inc (DRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dicerna Pharmaceuticals Inc (DRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dicerna Pharmaceuticals Inc Insider Transactions

No Available Data

What does Mersana Therapeutics Inc do?

Who are the key executives at Mersana Therapeutics Inc?

Anna Protopapas is the director & President and CEO of Mersana Therapeutics Inc. Other key executives at Mersana Therapeutics Inc include Chief Legal Officer Alejandra Carvajal , SVP & Chief Development Officer Mohan Bala , and Chief Manufacturing Officer Tushar Misra .

Mersana Therapeutics Inc (MRSN) Insider Trades Summary

Over the past 18 months, Anna Protopapas made 2 insider transaction in Mersana Therapeutics Inc (MRSN) with a net sale of 46,745. Other recent insider transactions involving Mersana Therapeutics Inc (MRSN) include a net sale of 9,107 shares made by Alejandra Carvajal , a net sale of 5,723 shares made by Tushar Misra , and a net sale of 16,642 shares made by Timothy B Lowinger .

In summary, during the past 3 months, insiders sold 0 shares of Mersana Therapeutics Inc (MRSN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 114,354 shares of Mersana Therapeutics Inc (MRSN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 114,354 shares.

Mersana Therapeutics Inc (MRSN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mersana Therapeutics Inc Insider Transactions

No Available Data

What does Bioverativ Inc do?

Who are the key executives at Bioverativ Inc?

Anna Protopapas is the director of Bioverativ Inc. Other key executives at Bioverativ Inc include director & Chief Executive Officer John Cox , EVP & CFO and Treasurer John Greene , and Chief Accounting Officer Diantha Duvall .

Bioverativ Inc (BIVV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Bioverativ Inc (BIVV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Bioverativ Inc (BIVV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Bioverativ Inc (BIVV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bioverativ Inc Insider Transactions

No Available Data

What does ARIAD Pharmaceuticals Inc do?

Who are the key executives at ARIAD Pharmaceuticals Inc?

Anna Protopapas is the director of ARIAD Pharmaceuticals Inc. Other key executives at ARIAD Pharmaceuticals Inc include EVP & CFO & Treasurer Manmeet Singh Soni , SVP & Chief Business Officer Hugh M Cole , and director & President and CEO Paris Panayiotopoulos .

ARIAD Pharmaceuticals Inc (ARIA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ARIAD Pharmaceuticals Inc (ARIA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARIAD Pharmaceuticals Inc (ARIA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ARIAD Pharmaceuticals Inc (ARIA)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARIAD Pharmaceuticals Inc Insider Transactions

No Available Data

What does Nuvalent Inc do?

Who are the key executives at Nuvalent Inc?

Anna Protopapas is the director of Nuvalent Inc. Other key executives at Nuvalent Inc include Chief Legal Officer Deborah Ann Miller , See Remarks Darlene Noci , and Chief Financial Officer Alexandra Balcom .

Nuvalent Inc (NUVL) Insider Trades Summary

Over the past 18 months, Anna Protopapas made 1 insider transaction in Nuvalent Inc (NUVL) with a net sale of 5,000. Other recent insider transactions involving Nuvalent Inc (NUVL) include a net sale of 135,400 shares made by Darlene Noci , a net sale of 94,578 shares made by Deborah Ann Miller , and a net sale of 579,494 shares made by Matthew Shair .

In summary, during the past 3 months, insiders sold 1,132,833 shares of Nuvalent Inc (NUVL) in total and bought 0 shares, with a net sale of 1,132,833 shares. During the past 18 months, 1,791,365 shares of Nuvalent Inc (NUVL) were sold and 799,253 shares were bought by its insiders, resulting in a net sale of 992,112 shares.

Nuvalent Inc (NUVL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nuvalent Inc Insider Transactions

No Available Data

Anna Protopapas Mailing Address

Above is the net worth, insider trading, and ownership report for Anna Protopapas. You might contact Anna Protopapas via mailing address: Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge Ma 02139.

Discussions on Anna Protopapas

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.